{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:53:38Z","timestamp":1790834018119,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Poverty"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The elimination of <jats:italic>Plasmodium vivax<\/jats:italic> malaria requires 8-aminoquinolines, which are contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to the risk of acute haemolytic anaemia. Several point-of-care devices have been developed to detect G6PD deficiency. The objective of the present study was to evaluate the performance of two of these devices against G6PD genotypes in Mauritania.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Outpatients were screened for G6PD deficiency using CareStart\u2122 rapid diagnostic test (RDT) and CareStart\u2122 G6PD biosensor in Nouakchott, Mauritania, in 2019\u20132020. African-type and Mediterranean-type G6PD genotypes commonly observed in Africa were determined by polymerase chain reaction-restriction fragment length polymorphism and sequencing. Qualitative variables were compared using Fisher\u2019s exact test.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 323 patients (74 males and 249 females), 5 males and 2 homozygous females had the African-type A- genotype: A<jats:sup>\u2212(202)<\/jats:sup> in 3 males and 2 females and G6PD A<jats:sup>\u2212(968)<\/jats:sup> in 2 males. Among heterozygous females, 13 carried G6PD A<jats:sup>\u2212(202)<\/jats:sup>, 12 G6PD A<jats:sup>\u2212(968)<\/jats:sup>, and 3 G6PD A<jats:sup>\u2212(542)<\/jats:sup> variants. None had the Mediterranean-type G6PD genotype. Eight had a positive G6PD RDT result, including all 7 hemizygous males and homozygous females with A- or A-A- (0.12 to 2.34\u00a0IU\/g haemoglobin, according to G6PD biosensor), but RDT performed poorly (sensitivity, 11.1% at the cut-off level of\u2009&lt;\u200930%) and yielded many false negative tests. Thirty-seven (50.0%) males and 141 (56.6%) females were anaemic. The adjusted median values of G6PD activity were 5.72 and 5.34\u00a0IU\/g haemoglobin in non-anaemic males (<jats:italic>n<\/jats:italic>\u2009=\u200935) and non-anaemic males and females (<jats:italic>n<\/jats:italic>\u2009=\u2009130) with normal G6PD genotypes using G6PD biosensor, respectively. Based on the adjusted median of 5.34\u00a0IU\/g haemoglobin, the performance of G6PD biosensor against genotyping was as follows: at 30% cut-off, the sensitivity and specificity were 85.7% and 91.7%, respectively, and at 80% cut-off, the sensitivity was 100% while the specificity was 64.9%.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Although this pilot study supports the utility of biosensor to screen for G6PD deficiency in patients, further investigation in parallel with spectrophotometry is required to promote and validate a more extensive use of this point-of-care device in areas where <jats:italic>P. vivax<\/jats:italic> is highly prevalent in Mauritania.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphic abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s40249-021-00889-2","type":"journal-article","created":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T08:04:07Z","timestamp":1628150647000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Assessment of CareStart G6PD rapid diagnostic test and CareStart G6PD biosensor in Mauritania"],"prefix":"10.1186","volume":"10","author":[{"given":"Oum Kelthoum Mamadou","family":"Djigo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yacoub","family":"Ould Khalef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Salem","family":"Ould Ahmedou Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Basco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Briolant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Ould Mohamed Salem Boukhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,5]]},"reference":[{"issue":"12","key":"889_CR1","doi-asserted-by":"publisher","first-page":"4157","DOI":"10.1073\/pnas.83.12.4157","volume":"83","author":"T Takizawa","year":"1986","unstructured":"Takizawa T, Huang IY, Ikuta T, Yoshida A. Human glucose-6-phosphate dehydrogenase: primary structure and cDNA cloning. Proc Natl Acad Sci USA. 1986;83(12):4157\u201361.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"889_CR2","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/0888-7543(91)90465-Q","volume":"10","author":"EY Chen","year":"1991","unstructured":"Chen EY, Cheng A, Lee A, Kuang WJ, Hillier L, Green P, et al. Sequence of human glucose-6-phosphate dehydrogenase cloned in plasmids and a yeast artificial chromosome. Genomics. 1991;10(3):792\u2013800.","journal-title":"Genomics"},{"issue":"2","key":"889_CR3","first-page":"243","volume":"45","author":"A Yoshida","year":"1971","unstructured":"Yoshida A, Beutler E, Motulsky AG. Human glucose-6-phosphate dehydrogenase variants. Bull World Health Organ. 1971;45(2):243\u201353.","journal-title":"Bull World Health Organ"},{"issue":"3","key":"889_CR4","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.bcmd.2012.01.001","volume":"48","author":"A Minucci","year":"2012","unstructured":"Minucci A, Moradkhani K, Hwang MJ, Zuppi C, Giardina B, Capoluongo E. Glucose-6-phosphate dehydrogenase (G6PD) mutations database: review of the \u201cold\u201d and update of the new mutations. Blood Cells Mol Dis. 2012;48(3):154\u201365.","journal-title":"Blood Cells Mol Dis"},{"issue":"12","key":"889_CR5","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.3390\/ijms17122069","volume":"17","author":"S G\u00f3mez Manzo","year":"2016","unstructured":"G\u00f3mez Manzo S, Marcial Quino J, Vanoye Carlo A, Serrano Posada H, Ortega Cuellar D, Gonz\u00e1lez Valdez A, et al. Glucose-6-phosphate dehydrogenase: update and analysis of new mutations around the world. Int J Mol Sci. 2016;17(12):2069.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"889_CR6","first-page":"601","volume":"67","author":"World Health Organization Working Group","year":"1989","unstructured":"World Health Organization Working Group. Glucose-6-phosphate dehydrogenase deficiency. Bull World Health Organ. 1989;67(6):601\u201311.","journal-title":"Bull World Health Organ"},{"key":"889_CR7","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/B978-0-12-407826-0.00004-7","volume":"81","author":"RE Howes","year":"2013","unstructured":"Howes RE, Battle KE, Satyagraha AW, Baird JK, Hay SI. G6PD deficiency: global distribution, genetic variants and primaquine therapy. Adv Parasitol. 2013;81:133\u2013201.","journal-title":"Adv Parasitol"},{"key":"889_CR8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1001\/archinte.1962.03620140081013","volume":"109","author":"AR Tarlov","year":"1962","unstructured":"Tarlov AR, Brewer GJ, Carson PE, Alving AS. Primaquine sensitivity: glucose-6-phosphate dehydrogenase deficiency: an inborn error of metabolism of medical and biological significance. Arch Intern Med. 1962;109:209\u201334.","journal-title":"Arch Intern Med"},{"issue":"2","key":"889_CR9","first-page":"165","volume":"35","author":"RL Degowin","year":"1966","unstructured":"Degowin RL, Eppes RB, Powell RD, Carson PE. The haemolytic effects of diaphenylsulfone (DDS) in normal subjects and in those with glucose-6-phosphate-dehydrogenase deficiency. Bull World Health Organ. 1966;35(2):165\u201379.","journal-title":"Bull World Health Organ"},{"issue":"1","key":"889_CR10","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/j.1708-8305.1994.tb00554.x","volume":"1","author":"GD Shanks","year":"1994","unstructured":"Shanks GD. Drugs for prophylaxis and treatment of malaria. J Travel Med. 1994;1(1):40\u20137.","journal-title":"J Travel Med"},{"issue":"9742","key":"889_CR11","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S0140-6736(10)60396-0","volume":"376","author":"L Luzzatto","year":"2010","unstructured":"Luzzatto L. The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics. Lancet. 2010;376(9742):739\u201341.","journal-title":"Lancet"},{"issue":"20","key":"889_CR12","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.1182\/blood-2012-03-416032","volume":"120","author":"A Pamba","year":"2012","unstructured":"Pamba A, Richardson ND, Carter N, Duparc S, Premji Z, Tiono AB, et al. Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone. Blood. 2012;120(20):4123\u201333.","journal-title":"Blood"},{"issue":"4","key":"889_CR13","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/pds.3370","volume":"22","author":"O M\u00fcller","year":"2013","unstructured":"M\u00fcller O, Mockenhaupt FP, Marks B, Meissner P, Coulibaly B, Kuhnert R, et al. Haemolysis risk in methylene blue treatment of G6PD-sufficient and G6PD-deficient West-African children with uncomplicated falciparum malaria: a synopsis of four RCTs. Pharmacoepidemiol Drug Saf. 2013;22(4):376\u201385.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"889_CR14","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2147\/IDR.S151031","volume":"12","author":"AB Hounkpatin","year":"2019","unstructured":"Hounkpatin AB, Kreidenweiss A, Held J. Clinical utility of tafenoquine in the prevention of relapse of Plasmodium vivax malaria: a review on the mode of action and emerging trial data. Infect Drug Resist. 2019;12:553\u201370.","journal-title":"Infect Drug Resist"},{"issue":"2","key":"889_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1182\/blood.V14.2.103.103","volume":"14","author":"E Beutler","year":"1959","unstructured":"Beutler E. The hemolytic effect of primaquine and related compounds: a review. Blood. 1959;14(2):103\u201339.","journal-title":"Blood"},{"key":"889_CR16","unstructured":"WHO. Guidelines for the treatment of malaria. Third edition. Geneva, Switzerland: World Health Organization Publications; 2015. https:\/\/www.afro.who.int\/publications\/guidelines-treatment-malaria-third-edition (accessed 7 July 2021)."},{"key":"889_CR17","unstructured":"Recht J, Ashley E, White N. Safety of 8-aminoquinoline antimalarial medicines. Geneva, Switzerland: World Health Organization Publications; 2014. https:\/\/apps.who.int\/iris\/handle\/10665\/112735 (accessed 7 July 2021)."},{"key":"889_CR18","unstructured":"WHO. Policy brief on single-dose primaquine as a gametocytocide in Plasmodium falciparum malaria. WHO\/HTM\/GMP\/2015.1; Geneva, Switzerland; World Health Organization Publication; 2015. https:\/\/apps.who.int\/iris\/handle\/10665\/338498 (accessed 7 July 2021)."},{"issue":"2","key":"889_CR19","first-page":"CD008152","volume":"2","author":"PM Graves","year":"2018","unstructured":"Graves PM, Choi L, Gelband H, Garner P. Primaquine or other 8-aminoquinolines for reducing Plasmodium falciparum transmission. Cochrane Database Syst Rev. 2018;2(2):CD008152.","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"889_CR20","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1080\/14787210.2016.1220304","volume":"14","author":"CS Chu","year":"2016","unstructured":"Chu CS, White NJ. Management of relapsing Plasmodium vivax malaria. Expert Rev Anti Infect Ther. 2016;14(10):885\u2013900.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"3","key":"889_CR21","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/NEJMoa1710775","volume":"380","author":"MVG Lacerda","year":"2019","unstructured":"Lacerda MVG, Llanos-Cuentas A, Krudsood S, Lon C, Saunders DL, Mohammed R, et al. Single-dose tafenoquine to prevent relapse of Plasmodium vivax malaria. N Engl J Med. 2019;380(3):215\u201328.","journal-title":"N Engl J Med"},{"issue":"3","key":"889_CR22","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJMoa1802537","volume":"380","author":"A Llanos-Cuentas","year":"2019","unstructured":"Llanos-Cuentas A, Lacerda MVG, Hien TT, V\u00e9lez ID, Namaik-Larp C, Chu CS, et al. Tafenoquine versus primaquine to prevent relapse of Plasmodium vivax malaria. N Engl J Med. 2019;380(3):229\u201341.","journal-title":"N Engl J Med"},{"key":"889_CR23","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12936-015-0607-5","volume":"14","author":"KM Lekweiry","year":"2015","unstructured":"Lekweiry KM, Salem MS, Basco LK, Briolant S, Hafid J, Boukhary AO. Malaria in Mauritania: retrospective and prospective overview. Malar J. 2015;14:100.","journal-title":"Malar J"},{"key":"889_CR24","unstructured":"WHO. Guidelines for the treatment of malaria. 2nd edition. Geneva, Switzerland: World Health Organization Publication; 2010. https:\/\/www.paho.org\/en\/node\/50095 (accessed 7 July 2021)."},{"key":"889_CR25","unstructured":"Mauritanian Ministry of Health. Guide clinique et th\u00e9rapeutique \u00e0 l\u2019usage du personnel des centres de sant\u00e9 de la Mauritanie. 2nd ed. Madrid: Agencia Espa\u00f1ola de Cooperaci\u00f3n Internacional para el Desarrollo (AECID); 2013. http:\/\/www.sante.gov.mr\/?wpfb_dl=140 (accessed 9 April 2021)."},{"key":"889_CR26","unstructured":"WHO. Standardization of procedures for the study of glucose-6-phosphate dehydrogenase. WHO Tech Rep Ser 366. Geneva, Switzerland: World Health Organization Publication; 1967. https:\/\/apps.who.int\/iris\/handle\/10665\/40660 (accessed 7 July 2021)."},{"key":"889_CR27","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1186\/1475-2875-12-391","volume":"12","author":"GJ Domingo","year":"2013","unstructured":"Domingo GJ, Satyagraha AW, Anvikar A, Baird K, Bancone G, Bansil P, et al. G6PD testing in support of treatment and elimination of malaria: recommendations for evaluation of G6PD tests. Malar J. 2013;12:391.","journal-title":"Malar J"},{"issue":"1","key":"889_CR28","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1186\/s12936-017-2017-3","volume":"16","author":"B Ley","year":"2017","unstructured":"Ley B, Bancone G, von Seidlein L, Thriemer K, Richards JS, Domingo GJ, et al. Methods for the field evaluation of quantitative G6PD diagnostics: a review. Malar J. 2017;16(1):361.","journal-title":"Malar J"},{"issue":"5","key":"889_CR29","doi-asserted-by":"publisher","first-page":"e1003084","DOI":"10.1371\/journal.pmed.1003084","volume":"17","author":"DA Pfeffer","year":"2020","unstructured":"Pfeffer DA, Ley B, Howes RE, Adu P, Alam MS, Bansil P, et al. Quantification of glucose-6-phosphate dehydrogenase activity by spectrophotometry: a systematic review and meta-analysis. PLoS Med. 2020;17(5):e1003084.","journal-title":"PLoS Med"},{"issue":"4","key":"889_CR30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/ijns4040034","volume":"4","author":"A Anderle","year":"2018","unstructured":"Anderle A, Bancone G, Domingo GJ, Gerth-Guyette E, Pal S, Satyagraha AW. Point-of-care testing for G6PD deficiency: opportunities for screening. Int J Neonatal Screen. 2018;4(4):34.","journal-title":"Int J Neonatal Screen"},{"key":"889_CR31","unstructured":"WHO. Malaria Policy Advisory Committee Meeting. Point-of-care G6PD testing to support safe use of primaquine for the treatment of vivax malaria. WHO Evidence Review Group meeting report, 8\u20139 October 2014; Geneva, Switzerland, 2015; WHO\/HTM\/GMP\/MPAC\/2015.6. http:\/\/www.who.int\/malaria\/mpac\/mpac-mar2015-erg-g6pd-presentation.pdf (accessed 7 July 2021)."},{"issue":"8","key":"889_CR32","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1093\/cid\/ciz124","volume":"69","author":"MP Grobusch","year":"2019","unstructured":"Grobusch MP, Rodr\u00edguez-Morales AJ, Schlagenhauf P. The primaquine problem-and the solution? Point-of-care diagnostics for glucose-6-phosphate dehydrogenase deficiency. Clin Infect Dis. 2019;69(8):1443\u20135.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"889_CR33","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/0888-7543(87)90048-6","volume":"1","author":"T Takizawa","year":"1987","unstructured":"Takizawa T, Yoneyama Y, Miwa S, Yoshida A. A single nucleotide base transition is the basis of the common human glucose-6-phosphate dehydrogenase variant A (+). Genomics. 1987;1(3):228\u201331.","journal-title":"Genomics"},{"issue":"11","key":"889_CR34","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1073\/pnas.85.11.3951","volume":"85","author":"A Hirono","year":"1988","unstructured":"Hirono A, Beutler E. Molecular cloning and nucleotide sequence of cDNA for human glucose-6-phosphate dehydrogenase variant A(-). Proc Natl Acad Sci USA. 1988;85(11):3951\u20134.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"889_CR35","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1182\/blood.V74.7.2550.bloodjournal7472550","volume":"74","author":"E Beutler","year":"1989","unstructured":"Beutler E, Kuhl W, Vives-Corrons JL, Prchal JT. Molecular heterogeneity of glucose-6-phosphate dehydrogenase A-. Blood. 1989;74(7):2550\u20135.","journal-title":"Blood"},{"key":"889_CR36","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/1475-2875-10-241","volume":"10","author":"N Carter","year":"2011","unstructured":"Carter N, Pamba A, Duparc S, Waitumbi JN. Frequency of glucose-6-phosphate dehydrogenase deficiency in malaria patients from six African countries enrolled in two randomized anti-malarial clinical trials. Malar J. 2011;10:241.","journal-title":"Malar J"},{"issue":"14","key":"889_CR37","doi-asserted-by":"publisher","first-page":"5171","DOI":"10.1073\/pnas.85.14.5171","volume":"85","author":"TJ Vulliamy","year":"1988","unstructured":"Vulliamy TJ, D\u2019Urso M, Battistuzzi G, Estrada M, Foulkes NS, Martini G, et al. Diverse point mutations in the human glucose-6-phosphate dehydrogenase gene cause enzyme deficiency and mild or severe hemolytic anemia. Proc Natl Acad Sci USA. 1988;85(14):5171\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"889_CR38","first-page":"575","volume":"47","author":"JL Vives-Corrons","year":"1990","unstructured":"Vives-Corrons JL, Kuhl W, Pujades MA, Beutler E. Molecular genetics of the glucose-6-phosphate dehydrogenase (G6PD) Mediterranean variant and description of a new G6PD mutant, G6PD Andalus1361A. Am J Hum Genet. 1990;47(3):575\u20139.","journal-title":"Am J Hum Genet"},{"issue":"3","key":"889_CR39","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1309\/LMQOSC1RY6ECTDU2","volume":"44","author":"ZM Ezz El-Deen","year":"2013","unstructured":"Ezz El-Deen ZM, Hussin NF, Abdel Hamid TA, Abdel Migeed OR, Samy RM. G6PD deficiency and G6PD (Mediterranean and silent) polymorphisms in Egyptian infants with neonatal hyperbilirubinemia. Lab Med. 2013;44(3):228\u201334.","journal-title":"Lab Med"},{"key":"889_CR40","unstructured":"WHO. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. WHO\/NMH\/NHD\/MNM\/11.1, Vitamin and Mineral Nutrition Information System. Geneva, Switzerland: World Health Organization Publication; 2011. (http:\/\/www.who.int\/vmnis\/indicators\/haemoglobin.pdf) (accessed 7 July 2021)."},{"issue":"9","key":"889_CR41","doi-asserted-by":"publisher","first-page":"0220977","DOI":"10.1371\/journal.pone.0220977","volume":"14","author":"OKM Djigo","year":"2019","unstructured":"Djigo OKM, Bollahi MA, Hasni Ebou M, Ould Ahmedou Salem MS, Tahar R, Bogreau H, et al. Assessment of glucose-6-phosphate dehydrogenase activity using CareStart G6PD rapid diagnostic test and associated genetic variants in Plasmodium vivax malaria endemic setting in Mauritania. PLoS ONE. 2019;14(9):0220977.","journal-title":"PLoS ONE"},{"key":"889_CR42","doi-asserted-by":"crossref","unstructured":"Djigo OKM, Ould Ahmedou Salem MS, Diallo SM, Bollahi MA, Boushab MB, Garre A, et al. Molecular epidemiology of G6PD genotypes in different ethnic groups residing in Saharan and Sahelian zones of Mauritania. Pathogens. 2021;10:931.","DOI":"10.3390\/pathogens10080931"},{"issue":"4","key":"889_CR43","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.4269\/ajtmh.16-0714","volume":"97","author":"TA Weppelmann","year":"2017","unstructured":"Weppelmann TA, von Fricken ME, Wilfong TD, Aguenza E, Philippe TT, Okech BA. Field trial of the CareStart biosensor analyzer for the determination of glucose-6-phosphate dehydrogenase activity in Haiti. Am J Trop Med Hyg. 2017;97(4):1262\u201370.","journal-title":"Am J Trop Med Hyg"},{"issue":"11","key":"889_CR44","first-page":"0206331","volume":"13","author":"MS Alam","year":"2018","unstructured":"Alam MS, Kibria MG, Jahan N, Thriemer K, Hossain MS, Douglas NM, et al. Field evaluation of quantitative point of care diagnostics to measure glucose-6-phosphate dehydrogenase activity. PLoS ONE. 2018;13(11):0206331.","journal-title":"PLoS ONE"},{"issue":"5","key":"889_CR45","doi-asserted-by":"publisher","first-page":"0196716","DOI":"10.1371\/journal.pone.0196716","volume":"13","author":"G Bancone","year":"2018","unstructured":"Bancone G, Gornsawun G, Chu CS, Porn P, Pal S, Bansil P, et al. Validation of the quantitative point-of-care CareStart biosensor for assessment of G6PD activity in venous blood. PLoS ONE. 2018;13(5):0196716.","journal-title":"PLoS ONE"},{"issue":"1","key":"889_CR46","doi-asserted-by":"publisher","first-page":"213","DOI":"10.4269\/ajtmh.18-0612","volume":"100","author":"S Pal","year":"2019","unstructured":"Pal S, Bansil P, Bancone G, Hrutkay S, Kahn M, Gornsawun G, et al. Evaluation of a novel quantitative test for glucose-6-phosphate dehydrogenase deficiency: bringing quantitative testing for glucose-6-phosphate dehydrogenase deficiency closer to the patient. Am J Trop Med Hyg. 2019;100(1):213\u201321.","journal-title":"Am J Trop Med Hyg"},{"issue":"12","key":"889_CR47","doi-asserted-by":"publisher","first-page":"0226927","DOI":"10.1371\/journal.pone.0226927","volume":"14","author":"P Pengboon","year":"2019","unstructured":"Pengboon P, Thamwarokun A, Changsri K, Kaset C, Chomean S. Evaluation of quantitative biosensor for glucose-6-phosphate dehydrogenase activity detection. PLoS ONE. 2019;14(12):0226927.","journal-title":"PLoS ONE"},{"key":"889_CR48","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/190372a0","volume":"190","author":"MF Lyon","year":"1961","unstructured":"Lyon MF. Gene action in the X-chromosome of the mouse (Mus musculus L.). Nature. 1961;190:372\u20133.","journal-title":"Nature"},{"issue":"2","key":"889_CR49","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s00439-011-1013-x","volume":"130","author":"PS Harper","year":"2011","unstructured":"Harper PS. Mary Lyon and the hypothesis of random X chromosome inactivation. Hum Genet. 2011;130(2):169\u201374.","journal-title":"Hum Genet"},{"issue":"3","key":"889_CR50","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41431-018-0291-3","volume":"27","author":"E Shvetsova","year":"2019","unstructured":"Shvetsova E, Sofronova A, Monajemi R, Gagalova K, Draisma HHM, White SJ, et al. Skewed X-inactivation is common in the general female population. Eur J Hum Genet. 2019;27(3):455\u201365.","journal-title":"Eur J Hum Genet"},{"key":"889_CR51","unstructured":"WHO Malaria Policy Advisory Committee. Updating the WHO G6PD classification of variants and the International Classification of Diseases, 11th revision (ICD-11). WHO\/CDS\/GMP\/MPAC\/2019.15. Geneva, Switzerland: World Health Organization Publications; 2019. https:\/\/www.who.int\/malaria\/mpac\/mpac-october2019-session7-updating-G6PD-classification.pdf (accessed 7 July 2021)."}],"container-title":["Infectious Diseases of Poverty"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40249-021-00889-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40249-021-00889-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40249-021-00889-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T09:12:11Z","timestamp":1628154731000},"score":1,"resource":{"primary":{"URL":"https:\/\/idpjournal.biomedcentral.com\/articles\/10.1186\/s40249-021-00889-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,5]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["889"],"URL":"https:\/\/doi.org\/10.1186\/s40249-021-00889-2","relation":{},"ISSN":["2049-9957"],"issn-type":[{"value":"2049-9957","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,5]]},"assertion":[{"value":"19 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The purpose of the study was explained in local dialect to all adult patients, to the parents or legal guardians of paediatric patients, or to adolescents aged between 12 and 18\u00a0years old. Written informed consent was obtained from all adult participants, or from the parents or legal guardians accompanying children aged\u2009<\u200912\u00a0years old, before collection of blood samples. For adolescents aged 12\u201318\u00a0years old, their assent was also obtained in addition to their parents\u2019 or legal guardian\u2019s consent. The study protocol was reviewed and approved by the institutional ethics committee of the University of Nouakchott Al-Aasriya, Nouakchott, Mauritania (approval no. 112\/12-09-2014\/USTM, 003\/2020\/CE\/UNA) and the institutional review board of the Institut de Recherche pour le D\u00e9veloppement (IRD), Marseille, France (Comit\u00e9 consultative de d\u00e9ontologie et d\u2019\u00e9thique approval no. 15\/12\/2012).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"105"}}